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Abstract 
Hadron therapy has entered a new age [I]. The number 
of facilities grows steadily, and “consumer” interest is high. 
Some groups are working on new accelerator technology, 
while others optimize existing designs by reducing capi- 
tal and operating costs, and improving performance. This 
paper surveys the current requirements and directions in 
accelerator technology for hadron therapy. 
INTRODUCTION 
A whirlwind history conveniently introduces the major 
technologies [2]. Neutrons were the first hadrons to be 
used in therapy, in experiments that were underway by the 
end of the 1930’s [3]. At Harvard briefly in 1946, between 
the Manhattan project and Cornell, R.R. Wilson was asked 
to report on the danger of hadrons to humans. Instead he 
wrote a paper proposing to use protons or light ions in ther- 
apy [4]. Protons were first used in therapy at the LBL 
184 inch cyclotron in the mid 19503, followed by the first 
helium ions in 1957. 
Energy degraders were first used to achieve range modu- 
lation with proton beams from a cyclotron in the late 1950’s 
in Upssala. Neurological radio-surgery with cyclotron de- 
rived protons began in 1961 at MGH, where the worlds 
first fully-commercial in-hospital cyclotron was opened in 
1997. Russia was particularly active with proton therapy 
programs in the 1970’s, at JWR, ITEP and in St. Peters- 
burg. “Heavy” ions (typically carbon) began to be used 
at LBL in 1975 in the BEVELAC, the worlds first hadron 
therapy synchrotron, which first introduced beam wobbling 
(to laterally spread the beam) and beam scanning [5]. A 
proton therapy program began at PSI in 1984, where spot 
scanning techniques were pioneered in 1996. Patients be- 
gan to be treated with ions from HlMAC at Chiba in 1994. 
The worlds first hospital-based proton therapy facility 
opened at LLUMC in 1990, using a synchrotron that was 
designed and commissioned at FNAL. The worlds first su- 
perconducting gantry mounted cyclotron also began oper- 
ation in 1990, to generate neutrons at the Harper-Grace 
hospital. Precision raster scanning with carbon from a 
GSI synchrotron began in 1993, and the first patient was 
treated with carbon ions from two synchrotrons at HIMAC 
in Chiba in 1994 [6]. 
CLINICAL REQUIREMENTS 
A hadron therapy accelerator in a hospital or clinic must 
satisfy all of the following constraints: 
1. The accelerator must be easy to operate. The staff 
who routinely operate and maintain a facility are not 
as numerous as those in a national laboratory. 
2. Overall system availability must be greater than 95%, 
so accelerator availability should be greater than 99%. 
3. The accelerator must be compact - typically less than 
10 m across - in order to fit in a hospital building, or 
even in a single treatment room. 
4. The beam parameters must deliver the treatment 
planned for the patient. This is non-negotiable! 
Beam parameters 
Beam parameter requirements depend upon the treat- 
ment sites and modalities chosen by the physicians and 
medical physicists [7, 81. Basic Passive Scattering puts 
variable thickness material in the nozzle at the end of the 
gantry, to adjust the range of a broad beam to match the 
distal edge of the target volume and to scatter the beam. 
Higher beam currents and energies are required to com- 
pensate for this upstream material and also to compensate 
for cyclotron energy degraders. In pencil beam scanning 
the beam is dynamically steered transversely with magnets, 
and its range is adjusted by modulating the energy. Inten- 
sity Modulated Particle Therapy is pencil beam scanning 
with controlled beam intensity variation. IMPT enables the 
most conformal dose delivery. 
Approximate accelerator requirements can nonetheless 
be derived from simple clinical specifications of particle 
specie, penetration depth, dose rate and conformity. 
Penetration depth. A 250 MeV proton beam has a pene- 
tration depth of about 3 8 cm in water. An equivalent carbon 
ion beam has an energy of about 410 MeVh per nucleon. 
Required rigidities are therefore about 2.46 Tm and 6.50 
Tm, 2.64 times higher for carbon. 
Dose rate. The daily dose of typically around 2 Gray 
(Jkg) must be delivered in 1 or 2 minutes. A large 1 liter 
tumor therefore requires a modest average beam power of 
order only 0.02 W, corresponding to an average current of 
about 0.08 nA if the tumor is 25 cm deep. 
Conformity. The integrated dose must conform at the 1% 
or 2% level to the treatment plan within the treatment vol- 
ume, and should decrease sharply across the tumor surface. 
Scanning parameters 
A continuous beam from a cyclotron or slowly extracted 
from a synchrotron may pause at a sequence of control 
points during “point-and-shoot’’ 3D tumor scanning. Or, 
discrete beam pulses may be delivered to each of many 
voxels in sequence. “How few independent control points 
are needed to deliver the sharpest possible dose distribu- 
tion, limited only by the physics of multiple scattering and 
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energy straggling?’ The practical answer depends on treat- 
ment planning details and hadron specie, but under some 
assumptions an approximate scaling for protons is 
where f is a geometric form factor bigger than 1, and V is 
the treatment volume in liters [9]. The variation of N T ~ T  
with dose conformity is slow. Effective voxel repetition 
rates reported from PSI and MDACC are in the range 50 Hz 
to 70 Hz, with 5,000 to 10,000 voxels per liter on aver- 
age [lo]. This is reasonably consistent with Eqn. 1. A 
large 1 liter tumor can be treated in 100 s or more at 60 Hz. 
CYCLOTRONS 
Cyclotrons have relatively few adjustable parameters. 
Isochronous cyclotrons use a constant frequency RF system 
to accelerate CW beams to a constant output energy, with 
a beam current that can be continuously vaned with time 
at the ion source. Synchrocyclotrons use a swept frequency 
RF system to accelerator beam to higher (but constant) en- 
ergies than those possible with an isochronous cyclotron. 
However, the inherently smaller duty factor limits the beam 
delivery modalities that are available. The IBA (2230 
is a room temperature super-ferric (3 T) isochronous cy- 
clotron, delivering extracted currents of more than 300 nA 
at 230 MeV [I 11. The total weight of the iron core and the 
copper coils is 220 tons, in a 4 m diameter footprint, The 
first C230 went into operation at MGH in 1997. 
studies of isochronous cyclotrons and synchrocylotrons, 
using NbTi superconducting base coils to generate fields 
up to 5.5 T 11121. It was recognized that high field synchro- 
cyclotrons avoid the requirement of achieving sufficient az- 
imuthally field variation, a problem inherent to isochronous 
machines. At that time, however, superconducting syn- 
chrocyclotrons could not be built because of the problem 
of the required variable frequency RF system. 
The superconducting field coils in the COMET 
isochronous cyclotron built by ACCEL, shown in Fig. 1, 
are immersed in a liquid helium cryostat. They support 
high current densities and an intense magnetic field of sev- 
eral Tesla [13, 141. COMET weighs about 80 tons, within 
a footprint of about 3 m. It has a markedly better extraction 
efficiency than the C230. 
A gantry-mounted 70 MeV KlOO superconducting cy- 
clotron has been operating for neutron therapy at the Harper 
Grace hospital since 1990 [ 151. This pioneering demon- 
stration was followed by an effort towards higher field cy- 
clotrons with proton energies over 200 MeV, but still small 
enough to be gantry mounted for passive scattering beam 
delivery. Synchrocyclotrons with fields higher than 8 T de- 
livering 250 MeV protons have a mass of less than 35 tons. 
MIT and SRS are developing a gantry mounted compact 
high field superconducting 250 MeV synchrocyclotron. It 
is innovative in using react-and-wind NbsSn technology 
enabled by the DOE Conductor Development Program, and 
also in using a set of GM-type cryocoolers to provide both 
steady state cooling and cool-down refrigeration [16]. The 
elimination of cryogens is expected to permit broad deploy- 
ment in single room systems. With a field of around 9 T, 
it weighs less than the KlOO cyclotron. Qualification test- 
ing of the first coil set is expected in fall 2007, with first 
clinical deployment in 2008. 
Figure 1 : COMET superconducting isochronous cyclotron 
(partially disassembled). 
pigure 2: LLUMC focusing 250 M ~ V  synchrotron. 
SYNCHROTRONS For a fixed energy (or penetration depth), the radius of a cyclotron decreases inversely with the magnetic field B, 
while the mass and volume scale like B P 3 .  This scaling 
was explored during the 1980’s in feasibility and design 
The Loma Linda weak focusing slow extraction 
250 MeV proton synchrotron shown in Fig. 2 still pro- 
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vides the standard against which other synchrotrons are 
measured [ 171. The Hitachi strong-focusing synchrotron 
advanced to enable synchronization of beam delivery with 
patient respiration [18]. Synchrotrons are said to be better 
suited than cyclotrons to the acceleration of higher-rigidity 
ions [19]. Nonetheless, more than one group is design- 
ing superconducting cyclotrons for ion delivery. Antipro- 
ton delivery would strongly favor synchrotrons, because of 
the vital need for high efficiency [20]. 
To date all operating synchrotrons use slow extrac- 
tion: quadrupole driven resonant extraction, acceleration- 
driven, RF hockout, betatron core, or stochastic 
noise [Zl]. Slow extraction, often with associated feedback 
systems, runs counter to the desire for ease of operation 
and high availability. Sometimes only a modest number of 
extraction energies are possible, and the transverse emit- 
tance and size of the beam are usually severely distorted in 
the process. Nonetheless, slow controlled extraction per- 
mits continuous raster scanning with IMPT, or “point-and- 
shoot” pseudo-voxel scanning. 
Figure 3: RCMS Rapid Cycling Medical Synchrotron. 
Rapid cycling proton synchrotrons with fast (single turn) 
extraction are currently at various states of design and de- 
velopment, with repetition rates in the range from 25 to 
60 Hz [22]. The energy and intensity of beam extracted on 
each cycle should be reliably variable over the entire dy- 
namic range from one pulse to the next, offering extreme 
clinical flexibility. Rapid cycling synchrotrons face 3 tech- 
nical challenges. First, the relativistic speed of a proton 
sweeps from p = 0.12 to p = 0.61 in the BNL RCMS 
design shown in Fig. 3 ,  and so the RF frequency swings 
from 1.2 MHz to 6.0 MHz in a matter of milliseconds [23]. 
The second challenge, of strong Eddy currents, has already 
been met in magnets in the 50 Hz ISIS and 60 Hz Cor- 
ne11 synchrotrons - and even in transformers. The third 
challenge is to install fast response beam diagnostics in 
the beam delivery nozzle, capable of accurately monitor- 
ing bunches about 100 ns long. Overcoming these chal- 
lenges would lead to a simple and reliable synchrotron that 
efficiently delivers stable beam with small emittance and 
energy spread, thanks to the absence of space charge ef- 
fects and slow extraction distortions [24]. Small beams en- 
able small, light and economical magnets which may not 
require water-cooling. 
NEW AND REVISITED CONCEPTS 
The proliferation of hadron therapy papers in these pro- 
ceedings illustrates the enthusiasm with which newer con- 
cepts are being considered and older concepts are being 
resurrected [25, 26, 271. The goal is to reduce the size of 
the accelerator, andor to improve the operational reliability 
and performance. A smaller and lighter accelerator moves 
towards either requiring or permitting one accelerator per 
treatment room, depending upon your point of view. 
Fixed Focusing Alternating Gradient (FFAG) 
There has been a rebirth of interest in the old idea of 
Fixed Focusing Alternating Gradient accelerators, which 
have a ring of magnets like a synchrotron, but operate at 
fixed field like a cyclotron [28]. The optics must accommo- 
date a large range of beam energies. FFAGs have the ad- 
vantage of very fast acceleration, an essential requirement 
for neutrino factories and muon colliders, where muons 
must be accelerated to relativistic speeds (to take advantage 
of time dilation) before they decay. Although the circum- 
ference can be smaller than an equivalent synchrotron, the 
magnets have much larger apertures. Fig. 4 shows the KEK 
proof-of-principle FFAG accelerator. The ultimate goal is 
to demonstrate variable energy extraction and acceptably 
high average beam currents [25,29]. 
Figure 4: The KEK proof-of-principle FFAG accelerator. 
Dielectric Wall Accelerator (D WA) linac 
Conventional LINACS typically have accelerating gra- 
dients of less than 10 MeVim, and are compromised in 
a trade-off between energy, length and complexity of the 
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RF system. They have mainly been limited to the non- 
hospital generation of fast neutrons, for example at FNAL, 
although the 200 MeV TOP proton linac under testing at 
ENEA in Frascati is destined for hospital use [30]. The Di- 
electric Wall Accelerator under development by LLNL and 
UC Davis promises gradients as high as 100 MeV/m, us- 
ing new dielectrics capable of holding off very high volt- 
ages [26, 311. Such an accelerator could produce short 
beam pulses, with pulse-by-pulse control of beam energy, 
size and intensity. It could be mounted on a robotic arm or 
on a small gantry. 
GANTRIES 
Extracted beam must be accurately directed in the right 
direction to the correct position in the patient. This trans- 
port may occur through a fixed beam line, but the most 
flexible arrangement is a fully rotating gantry. Loma Linda 
uses a corkscrew design to save space, while other imple- 
mentations are flat [32]. The size and weight of a gantry is 
given by a combination of the free space that must be al- 
lowed in the patient enclosure, the strength of the bending 
field, the rigidity of the beam and the required aperture in 
the magnets. Normal conducting proton gantries typically 
have a diameter of around 10 m, and a weight of around 
100 tons. 
The only ion gantry that has been built, at HIT in Hei- 
delberg, weighs 630 tons, due to the Carbon beam rigid- 
ity, its large transverse emittance and scanning sweep aper- 
ture [33]. Concepts to reduce the size of and weight of 
ion gantries include reduced rotation angles, superconduct- 
ing magnets and FFAG optics [29]. It may be possible to 
use direct-wind iron-free superconducting magnets, with 
cryogen-free cryocoolers. This is especially advantageous 
if the beam emittance is kept small, for example through 
the use of a rapid cycling synchrotron. 
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